Tuesday, March 26, 2019
Alphagan P Essays -- Drugs, Treating Glaucoma
There has been a new step in science guide towards evolution. Alphagan P has been recognized as the next leading pharmaceutical in treating Glaucoma. It is gentle to the ocular surface, unlike other musics which john harm it. Alphagan P provides IOP lowering which is comparable to beta blocker, but is without the unbecoming partakes that most other medications cause. It is an alpha-2 agonist, which is a class of drugs that bind to and stimulate alpha-2 adrenergic drug receptors, causing responses comparable to those of adrenaline and noradrenaline.Alphagan was first introduced in 1996. The latest propagation of adrenergic agonist is thrity times more selective for alpha 2 receptors than apraclonidine. Because of its selectivity, it does not include the alpha 1 side effects that affect the total and blood pressure. The most significant side effects argon drowsiness, a dry mouth, and fatigue. There is also surface irritation, with about 7 to 15 percent of patients experiencing a llergic conjunctivitis. Alphagan has stayed popular since it first came out patronage its side effects. What should you know about Alphagan P before using it? fix sure to not use brimonidine ophthalmic (Alphagan P) if you have used an monoamine oxidase inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the by 2 weeks. Inform your doctor if you have kidney or liver disease, heart disease, circulation problems such as Raynauds or Buergers disease, high blood pressure, have a history of fainting or low blood pressure. Make sure to not use the medication if you use contact lenses because the medication contains a protective that can be absorbed by soft contact lenses. If ... ...wing finished with their education. Studies are now being done to further investigate this occurrence. Although Alphagan P has a list of adverse reactions reported, it is still the most used medication used to treat patients with Glaucoma. Many clinical studies have been done on the drug since it came out in 1996, and further enhancements have been made since. plant life CitedOsborne, S., Montgomery, D., Morris, D., & McKay, I. (2005). Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye, 19(2), 129-137. inside10.1038/sj.eye.6701441Bowman, R. C., Cope, J. J., & Nischal, K. K. (2004). Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children. Eye, 18(1), 24-26. inside10.1038/sj.eye.6700520ALPHAGAN P THE NEXT STEP IN THE EVOLUTION OF GLAUCOMA THERAPY. (2003). Review of Ophthalmology, 10(9), 8.